Clinical trial
An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma
NCT00431769 · Janssen-Cilag International NV, Industry · Completed
Key facts
| NCT number | NCT00431769 |
|---|---|
| Title | An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma |
| Official title | A Phase II, Open-Label Trial Using Velcade for ReTreatment of Multiple Myeloma Subjects Following an Initial Response to Velcade |
| Lead sponsor | Janssen-Cilag International NV, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Bortezomib |
| Enrollment | 130 |
| Start date | Jun 1, 2006 |
| Primary completion | Feb 1, 2009 |
| Completion | Jan 1, 2010 |
| First posted | Feb 6, 2007 |
| Last update posted | May 12, 2014 |
| Countries | Austria, Belgium, France, Germany, Greece, Luxembourg, Portugal, Spain |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: